Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Was Ahmet Okumus’ Right About His Top Bets?

Page 1 of 3

New York-based long/short equity hedge fund Okumus Fund Management and its founder Ahmet Okumus are well-known in the value investing space. Mr. Ahmet started investing in the US stocks in 1992 with 15,000 borrowed from his mother and turned that investment into over $6 million by early 2000 by investing in undervalued stocks. He launched his first hedge fund, Okumus Opportunity Fund, in 1997 and has consistently generated impressive returns over the years. Mr. Okumus runs a fairly concentrated portfolio and makes big bets on the stocks he likes. According to Okumus Fund Management’s last submitted 13F filing its US equity portfolio at the end of September was worth $764 .22 million, up by 158.8% on the quarter. The filing also revealed that Okumus’ top 10 equity holdings amassed 96.26% of the value of its equity portfolio. Since Mr. Okumus makes large bets on the stocks he deems undervalued, in this article we will be analyzing the performance of the fund’s top five stock picks during the final quarter of 2015 and the beginning of 2016.

At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here).

Ahmet Okumus
Ahmet Okumus
Okumus Fund Management

#5 Ascent Capital Group Inc (NASDAQ:ASCMA)

– Shares Owned by Okumus Fund Management (as of September 30): 1.29 million

– Value of Holding (as of September 30): $35.3 million

During the second quarter of 2015, Okumus hiked its stake in Ascent Capital Group Inc (NASDAQ:ASCMA) by 449%  and during the third quarter, amid a 36% decline registered by the stock, Okumus increased its stake by another 50%. However, shares of Ascent Capital Group Inc (NASDAQ:ASCMA) continued their decline during the fourth quarter and lost another 39% on the back of weak financial results reported by the company. Overall, since the end of September, Ascent Capital Group’s stock has lost more than 50%.

Ascena Capital Group has not reported its financial results for its last quarter yet, but analysts project a net loss of $0.01 per share on revenue of $1.88 billion. Moreover, earlier this month, Goldman Sachs upgraded the stock to ‘Neutral’ from ‘Sell’ but maintained the price target at $7.00. Following the decline registered by the stock, it is trading at around 7.6 times forward earnings, which significantly below the S&P 500 average. One of the investors bullish on the stock is billionaire Jim Simons‘ Renaissance Technologies, which boosted its stake in Ascena Capital Group almost threefold to 553,940 shares during the fourth quarter of 2015.

#4 Lifelock Inc (NYSE:LOCK)

– Shares Owned by Okumus Fund Management (as of September 30): 8.84 million

– Value of Holding (as of September 30): $77.44 million

Shares of identity-theft protection provider Lifelock Inc (NYSE:LOCK) fell from a cliff during the third quarter after the U.S. Federal Trade Commission(FTC) announced allegations against the company that it was making ‘deceptive claims’ regarding safeguarding customers’ data. Nevertheless, Okumus Fund Management had made a wise decision to boost its position by 162% during that period and Lifelock Inc (NYSE:LOCK)’s stock surged by 64% during the fourth quarter after the company reached a tentative agreement with the FTC. According to the terms of the agreement Lifelock Inc won’t admit to any wrongdoings, but it will be paying $100 million – the largest monetary award obtained by the FTC in an order enforcement action – to settle the charges against it. In his third-quarter letter to investors, Ahmet Okumus said:

“After deep research into the FTC case, we believe there is a high likelihood that the outcome is significantly better than what the stock is pricing in. Trading at less than 5 times EV/FCF, LifeLock’s business is still performing very well despite the negative publicity. Lifelock has navigated challenges to their business before and we have confidence they will do it again.”

Follow Lifelock Inc. (NYSE:LOCK)
Trade (NYSE:LOCK) Now!

Page 1 of 3

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!